Description du projet
Des organes-sur-puce personnalisés pour le dépistage de médicaments dans la polyarthrite rhumatoïde
La polyarthrite rhumatoïde (PR) est une maladie auto-immune associée à une inflammation du liquide synovial qui tapisse les articulations. La réponse aux médicaments actuels est loin d’être optimale, et nécessite de meilleurs traitements. Le projet FLAMIN-GO, financé par l’UE, propose d’aller au delà des essais cliniques conventionnels pour tester l’efficacité de nouvelles modalités de traitement grâce au développement d’une plateforme d’organes-sur-puce. L’approche FLAMIN-GO utilise des biopsies de patients pour construire des modèles 3D qui imitent la complexité de l’articulation PR et peuvent être adaptés à chaque patient. L’idée est d’utiliser ces modèles pour une identification optimale des médicaments en moins de deux mois, offrant une approche plus rapide, plus rentable et plus éthique pour le dépistage des médicaments.
Objectif
FLAMIN-GO aims at developing an Organ-on-Chip technology for clinical trials on Rheumatoid Arthritis (RA). In RA, a number of unmet needs still persist particularly related to response/non-response of powerful but expensive drugs. Conventional clinical trials may address part of these challenges, but are time consuming, expensive and ethically ethically doubtful as part of the patients still fail to achieve disease benefits. Thus, the rheumatology community has a need for an alternative strategy that can deliver innovative trials.
FLAMIN-GO develops a personalized next-generation synovia-on-chip, that, by effectively mimicking the complexity of RA joint, will allow performing personalized clinical trials-on-chip. The solution will be based on design and fabrication of a multi-compartment microfluidic platform, for 3D culturing and perfusion of all the disease-relevant joint tissues. It focuses on synovia and synovial fluid, which are the pathogenetic targeted tissues, but including immune system, who sustain the disease, and cartilage and bone which are the end damaged tissues, leading to permanent disability. Starting from individual patient biopsies, this model seeks to replicate RA joints, thus allowing to test and allocate the best on-market drug for that patient in 1-2 months starting form biopsy. When validated, the platform will also be a turning point for i) pharma by enabling screening of new drugs reducing costs, time, and animal testing and for ii) translational research for identification of new biomarkers or therapeutic targets.
FLAMIN-GO consortium features a strong, well-balanced composition of hospital, academia and industry partners, who cover with complementary expertise the whole value chain. It gathers experts in the fields of rheumatology, material science, tissue engineering, nanotechnology, cell biology and 3D modelling, in a cohesive, transdisciplinary, multi-sectorial approach taking on the challenge to drive RA personalized care.
Champ scientifique
Mots‑clés
Programme(s)
Régime de financement
RIA - Research and Innovation actionCoordinateur
13100 Vercelli
Italie